- Autorzy:
-
Sverdlov, A.L.
Zamorano, P.
Aktaa, S.
Tocchetti, C. G.
Parrini, I.
Pudil, R.
Farmakis, D.
Badimon, L.
Szmit, S.
Barac, A.
Garrido Lopez, P.
Curigliano, G.
Lee, G.A.
Cohen-Solal, A.
Gulati, G.
Jurczak, Wojciech
Abdin, A.
Stephens, R.
Lyon, A.R
Yaseen, Israa F.
Gale, C.P.
Kirby, A.M.
Blaes, A.H.
Asteggiano, R.
Lopez-Fernandez, T.
Iakobishvili, Z. - Opis:
- Aims: To develop quality indicators (QIs) for the evaluation of the prevention and management of cancer therapy-related cardiovascular toxicity. Methods and results: We followed the European Society of Cardiology (ESC) methodology for QI development which comprises (i) identifying the key domains of care for the prevention and management of cancer therapy-related cardiovascular toxicity in patients on cancer treatment, (ii) performing a systematic review of the literature to develop candidate QIs, and (iii) selecting of the final set of QIs using a modified Delphi process. Work was undertaken in parallel with the writing of the 2022 ESC Guidelines on Cardio-Oncology and in collaboration with the European Haematology Association, the European Society for Therapeutic Radiology and Oncology and the International Cardio-Oncology Society. In total, 5 main and 9 secondary QIs were selected across five domains of care: (i) Structural framework, (ii) Baseline cardiovascular risk assessment, (iii) Cancer therapy related cardiovascular toxicity, (iv) Predictors of outcomes, and (v) Monitoring of cardiovascular complications during cancer therapy. Conclusion: We present the ESC Cardio-Oncology QIs with their development process and provide an overview of the scientific rationale for their selection. These indicators are aimed at quantifying and improving the adherence to guideline-recommended clinical practice and improving patient outcomes.
- Dostawca treści:
- Repozytorium Uniwersytetu Jagiellońskiego
Artykuł